A new player offering US-made ag spray drones is entering the market. Exedy Drones—one of a series of players attempting…

Personal care technology giant Philips has identified three technology trends revolutionizing the beauty industry: personalized guidance, at-home devices, and human connection. The central theme connecting the three is everyday routines evolving into moments of care. 

The Pitman Comms Visibility Index Report has named Croda as the winner in the beauty industry’s behind-the-scenes Generative Engine Optimization (GEO) search results. The B2B consultancy analysis of ChatGPT’s beauty sourcing recommendations highlights wide disparities across AI visibility. 

Why it matters: Fresenius wants to expand its biosimilar business substantially. To this end, the Germany-based health care group has signed an exclusive development agreement with Chinese contract development and manufacturing organization WuXi Biologics. The agreement gives Fresenius access to up to 37 identified biosimilar candidates over the next 10 years. Its existing portfolio of marketed molecules and those in development could consequently grow from 29 to as many as 66. According to Fresenius, the reference products targeted by these candidates generate combined sales of more than €370 billion at list prices.

Two of Asia’s largest beauty groups grew sales in the third quarter of 2026, but only one turned the growth into greater profits. South Korea’s Amorepacific Group lifted operating profit by nearly a quarter, while China’s Proya Cosmetics saw net profit drop over 60% as marketing costs climbed. 

Why it matters: In the Phase 1b/2 OPTIMIZE-1 trial, mitazalimab combined with modified FOLFIRINOX chemotherapy achieved a 42.1% confirmed response rate and median overall survival of 14.9 months in previously untreated metastatic pancreatic cancer, although the absence of a randomized comparator leaves its added benefit uncertain.

In October, Wittington Investments agreed to acquire Boots for US$8.9 billion. The European Parliament approved Omnibus VI, giving cosmetics makers more time to withdraw products containing carcinogenic, mutagenic, or reprotoxic (CMR) substances. 

Lynch Regenerative Medicine (LRM) has secured the US Food and Drug Administration’s (FDA) green light to advance to Phase 2b clinical trials on the efficacy and safety of its injectable platelet-derived growth factor (PDGF) for under-eye hollowing applications. 

The celebrity beauty landscape is becoming increasingly crowded as household names across the music and film industries sign on to cosmetics. While star-studded ambassadorships and ad campaigns have been an industry norm, recent launches show a wave of entrepreneurial spirit from A-listers.